| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 454 | 2021 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 326 | 2020 |
| Real-world experience with caplacizumab in the management of acute TTP T Dutt, RJ Shaw, M Stubbs, J Yong, B Bailiff, T Cranfield, MP Crowley, ... Blood, The Journal of the American Society of Hematology 137 (13), 1731-1740, 2021 | 151 | 2021 |
| Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... New England Journal of Medicine 389 (1), 33-44, 2023 | 145 | 2023 |
| Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy TA Eyre, HS Walter, S Iyengar, G Follows, M Cross, CP Fox, A Hodson, ... Haematologica 104 (2), e68, 2019 | 144 | 2019 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 127 | 2020 |
| Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients UKCLL Forum haematologica 101 (12), 1563, 2016 | 108 | 2016 |
| Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study JJ Castillo, G Itchaki, J Paludo, M Varettoni, C Buske, TA Eyre, JC Chavez, ... Blood, The Journal of the American Society of Hematology 133 (4), 299-305, 2019 | 102 | 2019 |
| Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ... Clinical Cancer Research 25 (14), 4264-4270, 2019 | 92 | 2019 |
| Chronic lymphocytic leukemia therapy guided by measurable residual disease T Munir, DA Cairns, A Bloor, D Allsup, K Cwynarski, A Pettitt, S Paneesha, ... New England Journal of Medicine 390 (4), 326-337, 2024 | 88 | 2024 |
| Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia J Klintman, N Appleby, B Stamatopoulos, K Ridout, TA Eyre, P Robbe, ... Blood, The Journal of the American Society of Hematology 137 (20), 2800-2816, 2021 | 85 | 2021 |
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ... Blood advances 4 (16), 3977-3989, 2020 | 82 | 2020 |
| Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients MR Wilson, TA Eyre, AA Kirkwood, N Wong Doo, C Soussain, S Choquet, ... Blood, The Journal of the American Society of Hematology 139 (16), 2499-2511, 2022 | 75 | 2022 |
| Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCR inhibitor setting: a UK wide analysis TA Eyre, AA Kirkwood, S Gohill, G Follows, R Walewska, H Walter, ... British journal of haematology 185 (4), 656-669, 2019 | 75 | 2019 |
| Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy R McCulloch, C Visco, TA Eyre, R Frewin, N Phillips, DL Tucker, ... British journal of haematology 189 (4), 684-688, 2020 | 74 | 2020 |
| Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is … TA Eyre, AA Kirkwood, J Wolf, C Hildyard, C Mercer, H Plaschkes, ... British journal of haematology 187 (2), 185-194, 2019 | 69 | 2019 |
| NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome TA Eyre, R Clifford, A Bloor, L Boyle, C Roberts, M Cabes, GP Collins, ... British journal of haematology 175 (1), 43-54, 2016 | 69 | 2016 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 68 | 2021 |
| Anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease TA Eyre, D Khan, GW Hall, GP Collins European journal of haematology 93 (6), 455-468, 2014 | 67 | 2014 |
| Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma ML Wang, W Jurczak, PL Zinzani, TA Eyre, CY Cheah, CS Ujjani, Y Koh, ... Journal of Clinical Oncology 41 (24), 3988-3997, 2023 | 65 | 2023 |
Graham CollinsOxfordایمیل تأیید شده در ouh.nhs.uk
